## Note
nid: 1484879813519
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#FirstAid::12_Neuro_&_Special_Senses::06_Pharm::13_Inhaled_Anesthetics, #AK_Step1_v11::#FirstAid::12_Neuro_&_Special_Senses::06_Pharm::13_Inhaled_Anesthetics::Malignant_Hyperthermia, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#Physeo::09_Pharm::14_Neuro::16_Inhaled_Anesthetics, #AK_Step1_v11::#Pixorize::03_Pharm::14_Anesthetics::Halothane_and_Fluranes, #AK_Step1_v11::#SketchyPharm::06_Neuro/Psych::02_Anesthetics_&_Analgesics::02_Inhaled_anesthetics,_dantrolene, #AK_Step1_v11::^Other::^HighYield::2-RelativelyHighYield, #AK_Step1_v11::^Systems::Neuro::Pharmacology
markdown: false

### Text
<div>
  What <u>genetic phenomenon</u> is associated with <b>malignant
  hyperthermia</b>?
</div>
<div>
  {{c1::Incomplete penetrance}}
</div>

### Extra
<i>some individuals who have the disease <u>genotype</u> do not
display the disease <u>phenotype</u></i>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<div>
  <i>First Aid Pharmacology: Neuro/Psych</i>
</div><img src="paste-608017045258243.jpg"><img src=
"paste-609537463681027.jpg"><img src="paste-611066472038403.jpg">
<div><img src="paste-44147968835587.jpg"></div>

### Sketchy
<img src=
"paste-c676ed63dfaf695f637568405527fef994f55500.png"><img src=
"paste-4c8caca7a0decfaf993cc3983b070afc9378be2f.png"> <a href=
"https://dashboard.sketchy.com/study/medical/courses/medical-pharmacology/units/medical-pharmacology-neuro-psych/videos/medical-pharmacology-neuropsych-anesthetics-and-analgesics-inhaled-anesthetics-dantrolene?utm_source=anki&utm_medium=partnership&utm_campaign=february_update&utm_content=medical">
Watch Inhaled anesthetics, dantrolene</a>

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_3.png"></a>
</div>

### Additional Resources
<img src="paste-c46ab29783fe64ea539947636845f4abf20ae250.jpg">
<div>
  <img src="big_58a43728a51ce.jpg">
  <div>
    <div>
      <div>
        Pathomechanisms and therapeutic approach in malignant
        hyperthermia
      </div>
    </div>
    <div>
      <div>
        <div>
          Approx. half of cases of malignant hyperthermia are
          associated with a mutation in the ryanodine receptor type
          1 (RyR-1). RyR-1 is located in the sarcoplasmic reticulum
          (SR) of skeletal and cardiac muscle. Physiologically,
          activated RyR-1 in the skeletal muscle interacts with the
          dihydropyridine receptor (DGPR), which results in calcium
          release from the SR into the sarcoplasm.
        </div>
        <div>
          (1) If a mutation in the RyR-1 is present, certain
          triggering substances may lead to a pathological
          stimulation of the receptor, which (2) results in
          uncontrolled opening and excessive release of calcium
          from the SR. The contractility of the skeletal muscle
          increases, which in return increases the metabolism. As
          the increased oxygen need can no longer be met, the
          cell's energy supply breaks down and the cell dies.
        </div>
        <div>
          (3) The first-line treatment for malignant hyperthermia
          is dantrolene, which interacts with RyR1 and prevents the
          release of calcium from the SR of the skeletal muscle.
        </div>
        <div>
          The mechanism shown here is simplified; research on the
          pathomechanism of the condition and the exact effect of
          dantrolene is ongoing.
        </div>
      </div>
    </div>
  </div>
</div>

### One by one

